Naomi Onda, Shinji Nakamichi, Mariko Hirao, Kuniko Matsuda, Masaru Matsumoto, Akihiko Miyanaga, Rintaro Noro, Akihiko Gemma, Masahiro Seike. Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression. Cancer science. 2024
Yasuhiro Kato, Masaru Matsumoto, Natsuki Takano, Mariko Hirao, Kuniko Matsuda, Takehiro Tozuka, Naomi Onda, Shinji Nakamichi, Susumu Takeuchi, Akihiko Miyanaga, et al. Induction of resistance to neurotrophic tropomyosin-receptor kinase inhibitors by HMGCS2 via a mevalonate pathway. Cancer medicine. 2024. 13. 12. e7393
Naoya Nishioka, Hisao Imai, Masahiro Endo, Akifumi Notsu, Kosei Doshita, Satoshi Igawa, Hiroshi Yokouchi, Takashi Ninomiya, Takaaki Tokito, Sayo Soda, et al. Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101). Targeted oncology. 2024. 19. 3. 423-433
Takehiro Tozuka, Rintaro Noro, Keisuke Yoshida, Satoshi Takahashi, Mariko Hirao, Kuniko Matsuda, Yasuhiro Kato, Shinji Nakamichi, Susumu Takeuchi, Masaru Matsumoto, et al. Phosphoproteomic Analysis Identified Mutual Phosphorylation of FAK and Src as a Mechanism of Osimertinib Resistance in EGFR-Mutant Lung Cancer. JTO clinical and research reports. 2024. 5. 4. 100668-100668
Shinji Nakamichi, Kaoru Kubota, Toshihiro Misumi, Tetsuro Kondo, Shuji Murakami, Yoshimasa Shiraishi, Hisao Imai, Daijiro Harada, Kazutoshi Isobe, Hidetoshi Itani, et al. Phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non-small-cell lung cancer: TORG1937 (DATE study). Clinical cancer research : an official journal of the American Association for Cancer Research. 2024
中嶋亘, 石野孔祐, 中道真仁, 松本優, 大橋隆治, 山本林. Elucidation of the mechanism of drug resistance acquisition in EGFR-Mutated Lung Adenocarcinoma. 日本分子生物学会年会プログラム・要旨集(Web). 2023. 46th
高嶋紗衣, 松本優, 福泉彩, 恩田直美, 中道真仁, 武内進, 宮永晃彦, 笠原寿郎, 寺崎泰弘, 清家正博. Retrospective study of association between TTF-1 expression and antitumor effects of platinum+pemetrexed and immune checkpoint inhibitor combination therapy for lung adenocarcinoma. 日本呼吸器学会誌(Web). 2023. 12
戸塚猛大, 野呂林太郎, 中道真仁, 武内進, 松本優, 宮永晃彦, 笠原寿郎, 清家正博. Combination chemotherapy and immunotherapy for non-squamous cell carcinoma patients over 70 years old. 日本呼吸器学会誌(Web). 2023. 12
磯博和, 宮永晃彦, 戸塚猛大, 村田亜香里, 佐藤陽三, 中道真仁, 武内進, 松本優, 齋藤好信, 笠原寿郎, et al. A retrospective study of the efficacy and safety for pleurodesis in patients with interstitial lung disease. 日本呼吸器学会誌(Web). 2023. 12
恩田直美, 中道真仁, 松本優, 宮永晃彦, 清家正博. Afatinib in combination with pemetrexed and carboplatin after refractory to first-line osimertinib treatment in NSCLC patients with EGFR mutation. 日本呼吸器学会誌(Web). 2023. 12
